Read by QxMD icon Read

Biodegradable polymer stent

F Soria, E Morcillo, A López de Alda, T Pastor, F M Sánchez-Margallo
One of the main wishes in the field of urinary catheters and stents is to arm them with biodegradable characteristics because we consider a failure of these devices the need for retrieval, the forgotten catheter syndrome as well as the adverse effects permanent devices cause after fulfilling their aim. The efforts focused in new designs, coatings and biomaterials aim to increase the biocompatibility of theses internal devices. Lately, there have been correct advances to answer the main challenges regarding biodegradable ureteral devices...
October 2016: Archivos Españoles de Urología
Akshit Peer, Rabin Dhakal, Rana Biswas, Jaeyoun Kim
We compare the rates of drug release from nanopatterned and flat biodegradable polymer surfaces, and observe significantly lower release rates from the nanopatterned surfaces. Specifically, we nanopattern poly(l-lactic acid) (PLLA), a biodegradable polymer frequently used for fabricating drug-eluting coronary stents, through microtransfer molding and solvent casting and investigate the nanopattern's impact on the release of sirolimus, an immunosuppressant agent, coated on the PLLA surface using high performance liquid chromatography/mass spectrometry...
October 5, 2016: Nanoscale
J Ribamar Costa, Daniel Chamié, Alexandre A C Abizaid, Expedito Ribeiro, George C Meireles, Maurício Prudente, Carlos A Campos, Juliana P Castro, Ricardo Costa, Pedro A Lemos
We sought to compare, by means of IVUS and OCT imaging, the performance of a novel sirolimus-eluting drug-eluting stent (DES) with biodegradable polymer (Inspiron™) to the Biomatrix™ DES. From the DESTINY trial, a total of 70 randomized patients (2:1) were enrolled in the IVUS substudy (Inspiron™, n = 46; Biomatrix™: n = 20) while 25 patients were evaluated with OCT (Inspiron™, n = 19; Biomatrix™: n = 06) at 9-month follow-up. The main endpoints were % of neointimal tissue obstruction (IVUS) and neointimal stut coverage (OCT) at 9 months...
October 6, 2016: International Journal of Cardiovascular Imaging
Matteo Ghione, Joanna J Wykrzykowska, Stephan Windecker, Patrick W Serruys, Pawel Buszman, Axel Linke, Hae Young Sohn, Roberto Corti, Diethmar Antoni, William Wijns, Rodrigo Estevez-Loureiro, Marie-Claude Morice, Gerrit-Anne Van Es, Robert Jan van Geuns, Peter Juni, Pedro Eerdmans, Ton De Vries, Stéphanie Konik, Carlo Di Mario
BACKGROUND: Few data are available on long-term follow-up of DES in the treatment of chronic total occlusion (CTO). The LEADERS CTO sub-study compared the long-term results in CTO and non-CTO lesions of a Biolimus A9™-eluting stent (BES) with a sirolimus-eluting stent (SES). METHODS: Among 1,707 patients enrolled in the prospective, multi-center, all-comers LEADERS trial, 81 with CTOs were treated with either a BES (n = 45) or a SES (n = 36). The primary endpoint was the occurrence of major adverse cardiac events (MACE): cardiac death, myocardial infarction (MI) and clinically-indicated target vessel revascularization (TVR)...
September 26, 2016: Cardiology Journal
Haijun Zhang, Xiangfei Wang, Wei Deng, Shenguo Wang, Junbo Ge, Egon Toft
BACKGROUND: The biodegradable polymer drug-eluting stents (DES) were developed to improve vascular healing. However, further data and longer-term follow-up are needed to confirm safety and efficacy of these stents. This randomized clinical trial aimed to compare safety and efficacy of 2 sirolimus-eluting stents (SES): Cordimax-a novel abluminal biodegradable polymer SES and Cypher Select-a durable polymer SES, at 9 months angiographic and 5-year clinical follow-up. METHODS: We randomized 402 patients with coronary artery disease to percutaneous coronary intervention with Cordimax (n = 202) or Cypher select (n = 200)...
September 2016: Medicine (Baltimore)
Qian Wang, Gang Fang, Yinghong Zhao, Guohui Wang, Tao Cai
Poly-L-lactide Acid (PLLA), as a credible biodegradable polymer-based material, can provide a promising amount of degradation time for vessel remodeling. Served as a sort of reliable intravascular implants, PLLA stents are expected to provide sufficient scaffolding to the target arteries without generating too much recoil after deployment. Besides, the stress and strain distribution should be as homogeneous as possible, and the stent conformability in fitting to the nature curvature of the vessels needs to be guaranteed...
August 31, 2016: Journal of the Mechanical Behavior of Biomedical Materials
Ryota Sakurai, Ivana Burazor, Heidi N Bonneau, Hideaki Kaneda
BACKGROUND: Both biodegradable polymer biolimus-eluting stents (BP-BES) and biocompatible durable polymer everolimus-eluting stents (DP-EES) have been developed to decrease the risk of late adverse events. However, their efficacy and safety beyond 1year after stent deployment still remain controversial. METHODS: We conducted a meta-analysis on randomized controlled trials (RCTs) comparing BP-BES with DP-EES in patients undergoing percutaneous coronary intervention in long-term follow up (beyond 1year), and compared the pooled estimates with those in mid-term follow up (within 1year)...
November 15, 2016: International Journal of Cardiology
Salvatore Cassese, Erion Xhepa, Adnan Kastrati
No abstract text is available yet for this article.
September 14, 2016: Heart: Official Journal of the British Cardiac Society
Carlo Briguori, Gabriella Visconti, Michael Donahue, Vito Di Palma, Francesca De Micco, Giuseppe Signoriello, Amelia Focaccio
INTRODUCTION: Stent delivery failure may occur especially when treating complex coronary artery stenosis. XLIMUS (CARDIONOVUM GmbH, Bonn, Germany) is a new sirolimus-eluting stent (SES) with the following features: 1) cobalt chromium stent platform, with low (73 μm) strut thickness, (2) biodegradable polymer, and 3) potent antiproliferative drug (Sirolimus). Preliminary data suggest that XLIMUS SES may be ideal for the treatment of complex lesions. METHODS: In this registry, we assessed the deliverability, safety, and efficacy of percutaneous coronary interventions (PCI) using the XLIMUS SES in patients undergoing elective PCI in native coronary vessels for complex de novo lesions, including severe calcification, severe tortuosity, and chronic total occlusion...
September 13, 2016: Journal of Interventional Cardiology
R Belibel, C Barbaud, L Mora
In order to reduce restenosis, the necessity to develop the appropriate coating material of metallic stent is a challenge for biomedicine and scientific research over the past decade. Therefore, biodegradable copolymers of poly((R,S)-3,3 dimethylmalic acid) (PDMMLA) were prepared in order to develop a new coating exhibiting different custom groups in its side chain and being able to carry a drug. This material will be in direct contact with cells and blood. It consists of carboxylic acid and hexylic groups used for hydrophilic and hydrophobic character, respectively...
December 1, 2016: Materials Science & Engineering. C, Materials for Biological Applications
Alberto Chisari, Anna Maria Pistritto, Raffaele Piccolo, Alessio La Manna, Gian Battista Danzi
The Ultimaster coronary stent system (Terumo Corporation, Tokyo, Japan) represents a new iteration in drug-eluting stent (DES) technology that has recently received the Conformité Européenne (CE) mark approval for clinical use. The Ultimaster is a thin-strut, cobalt chromium, biodegradable-polymer, sirolimus-eluting coronary stent. The high elasticity of the biodegradable-polymer (PDLLA-PCL) and the abluminal gradient coating technology are additional novel features of this coronary device. The Ultimaster DES has undergone extensive clinical evaluation in two studies: The CENTURY I and II trials...
2016: International Journal of Molecular Sciences
Ranjan Shetty, Jayesh Prajapati, Umesh Pai, Kiran Shetty
Objective. The objective of the MANIPAL-FLEX study was to evaluate the feasibility, preliminary safety, and efficacy of the Supraflex sirolimus-eluting stent (SES) implantation, in de novo coronary artery disease, using clinical and quantitative coronary angiography (QCA) follow-ups. Methods. This was a prospective, nonrandomized, multicenter, single-arm study that enrolled 189 patients with de novo coronary artery disease who were treated with the Supraflex SES. Of 189 patients enrolled, the first 61 consecutive patients who consented to a 9-month follow-up evaluation by QCA, irrespective of presence of symptoms, were to be followed up with angiography at 9 months...
2016: Scientifica
Alexandre A Barros, Shane Browne, Carlos Oliveira, Estevão Lima, Ana Rita C Duarte, Kevin E Healy, Rui L Reis
Upper urinary tract urothelial carcinoma (UTUC) accounts for 5-10% of urothelial carcinomas and is a disease that has not been widely studied as carcinoma of the bladder. To avoid the problems of conventional therapies, such as the need for frequent drug instillation due to poor drug retention, we developed a biodegradable ureteral stent (BUS) impregnated by supercritical fluid CO2 (scCO2) with the most commonly used anti-cancer drugs, namely paclitaxel, epirubicin, doxorubicin, and gemcitabine. The release kinetics of anti-cancer therapeutics from drug-eluting stents was measured in artificial urine solution (AUS)...
August 31, 2016: International Journal of Pharmaceutics
Gianluca Rigatelli, Fabio Dell'Avvocata, Marco Zuin, Dobrin Vassiliev, Alberto Mazza, Huy D Dinh
AIM: To assess feasibility and 1-year outcomes of ultrathin biodegradable polymer double stenting using a very minimal crushing (nano-crush technique) in a series of patients with large (≥2.5mm) complex coronary bifurcation. METHODS: From January 2015 to June 2016, patients referred for large (≥2.5mm) complex coronary bifurcation percutaneous coronary interventions (PCI) were enrolled to receive Orsiro (Biotronik Inc., Bulack, Switzerland) double stenting using a very minimal crush technique (nano-crush)...
July 20, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Gian Battista Danzi, Raffaele Piccolo, Bernard Chevalier, Philip Urban, Farzin Fath-Ordoubadi, Didier Carrie, Marcus Wiemer, Antonio Serra, William Wijns, Petr Kala, Amerigo Stabile, Javier Goicolea Ruigomez, Dragan Sagic, Peep Laanmets, Gerhard Strupp, Nick West
OBJECTIVE: To evaluate the long-term follow-up of the unrestricted use of a biodegradable polymer-coated drug-eluting stent in patients undergoing percutaneous coronary intervention (PCI). METHODS: The Nobori 2 study was a prospective, multicentre, observational registry evaluating the safety and the efficacy of the biodegradable polymer biolimus-eluting stent (BP-BES) among 3067 patients recruited at 125 international sites. The primary combined endpoint was a composite of cardiac death, myocardial infarction and target-lesion revascularisation (TLR)...
August 10, 2016: Heart: Official Journal of the British Cardiac Society
Yunjing Yang, Jiayan Lei, Wei Huang, Han Lei
BACKGROUND: A meta-analysis was performed to investigate the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SESs) compared with durable polymer drug-eluting stents (DP-DESs). METHODS: Online databases, including PubMed, EMBASE and the Cochrane Library, were searched for randomized controlled trials that compared BP-SESs and DP-DESs and reported rates of overall and cardiac mortality, myocardial infarction (MI), stent thrombosis (ST), target lesion revascularization (TLR), target vessel revascularization (TVR) and late lumen loss (LLL)...
November 1, 2016: International Journal of Cardiology
Lucila Navarro, Diana-Elena Mogosanu, Thijs de Jong, Astrid D Bakker, David Schaubroeck, Julio Luna, Ignacio Rintoul, Jan Vanfleteren, Peter Dubruel
Biocompatible polymeric coatings for metallic stents are desired, as currently used materials present limitations such as deformation during degradation and exponential loss of mechanical properties after implantation. These concerns, together with the present risks of the drug-eluting stents, namely, thrombosis and restenosis, require new materials to be studied. For this purpose, novel poly(polyol sebacate)-derived polymers are investigated as coatings for metallic stents. All pre-polymers reveal a low molecular weight between 3000 and 18 000 g mol(-1) ...
August 8, 2016: Macromolecular Bioscience
Anna Franzone, Masanori Taniwaki, Fabio Rigamonti, Dik Heg, Raffaele Piccolo, Marco Roffi, David Tüller, Olivier Muller, Andre Vuilliomenet, Stéphane Cook, Daniel Weilenmann, Christoph Kaiser, Peiman Jamshidi, Peter Jüni, Stephan Windecker, Thomas Pilgrim
AIMS: We sought to assess the performance of drug-eluting stents combining an ultrathin cobalt-chromium platform with a biodegradable polymer across categories of increasing SYNTAX score (SS). METHODS AND RESULTS: Patients included in the BIOSCIENCE trial and randomly allocated to treatment with biodegradable polymer sirolimus-eluting stents (BP-SES) or durable polymer everolimus-eluting stents (DP-EES) were categorised according to SS tertiles (low <8, medium 8-15, high >15)...
2016: EuroIntervention
Lisette Okkels Jensen, Per Thayssen, Michael Maeng, Jan Ravkilde, Lars Romer Krusell, Bent Raungaard, Anders Junker, Christian Juhl Terkelsen, Karsten Tange Veien, Anton Boel Villadsen, Anne Kaltoft, Hans-Henrik Tilsted, Knud Nørregaard Hansen, Jens Aaroe, Steen Dalby Kristensen, Henrik Steen Hansen, Svend Eggert Jensen, Morten Madsen, Hans Erik Bøtker, Klára Berencsi, Jens Flensted Lassen, Evald Høj Christiansen
BACKGROUND: Coronary drug-eluting stents with biodegradable polymers have been designed to improve safety and efficacy. METHODS AND RESULTS: The Scandinavian Organization for Randomized Trials With Clinical Outcome (SORT OUT) VII trial-a large-scale registry-based randomized, multicenter, single-blind, 2-arm, noninferiority trial-compared 2 biodegradable polymer drug-eluting stents: the thin-strut cobalt-chromium sirolimus-eluting Orsiro stent and the stainless steel biolimus-eluting Nobori stent in an all-comer patient population...
July 2016: Circulation. Cardiovascular Interventions
Qin-Hua Jin, Yun-Dai Chen, Feng Tian, Jun Guo, Jing Jing, Zhi-Jun Sun
BACKGROUND: Different stents implantation in ST-segment elevation myocardial infarction (STEMI) patients may influence the long term prognosis by affecting vessel healings after stenting. The aim of this study was to evaluate the vessel healings after implantation of drug eluting stents (DES) with biodegradable or durable polymer or of bare-metal stents (BMS) in patients with acute STEMI. METHODS: This study included 50 patients, who underwent follow up angiogram and optical coherence tomography (OCT) assessment about one year after percutaneous coronary intervention (PCI) for STEMI...
May 2016: Journal of Geriatric Cardiology: JGC
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"